Co-stimulation in T cell responses

Current Opinion in Immunology

Volumn 9, Issue 3, 1997, Pages 396-404

  Chambers, Cynthia A ^a   Allison, James P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; T LYMPHOCYTE RECEPTOR;

CELLULAR IMMUNITY; IMMUNOSTIMULATION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0030844271     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80087-8     Document Type: Article

References (83)

1. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism. of special interest J Exp Med. 184:1996;1-8 This presents an overview of the various models of anergy described in the current literature and attempts to provide a common mechanism for the different models of T cell unresponsiveness.
2. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell co-stimulation. Annu Rev Immunol. 14:1996;233-258.
3. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 15:1994;321-331.
4. Hathcock KS, Laszlo SG, Pucillo C, Linsley PS, Hodes RJ. Comparative analysis of B7-1 and B7-2 co-stimulatory ligands: expression and function. J Exp Med. 180:1994;631-640.
5. Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS, Ikehara S, et al. The tissue distribution of the B7-2 co-stimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med. 180:1994;1849-1860.
6. Lenschow DJ, Sperling AI, Cooke MP, Freeman G, Rhee L, Decker DC, Gray G, Nadler LM, Goodnow CC, Bluestone JA. Differential up-regulation of the B7-1 and B7-2 co-stimulatory molecules after Ig receptor engagement by antigen. J Immunol. 153:1994;1990-1997.
7. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA Jr, Flavell RA. Requirement for CD40 ligand in co-stimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 273:1996;1864-1867.
8. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 273:1996;1862-1864.
9. Vyth-Dreese FA, Dellemijn TAM, Majoor D, Dejong D. Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue. of special interest Eur J Immunol. 25:1995;3023-3029 This paper examines the spatial expression patterns of CD80, CD86, CD40, CD28 and CTLA-4 on sections of human tonsillar lymph nodes. There was an obvious gradient of expression of B7.1 and B7.2 within the germinal center. Furthermore, the results demonstrate the punctate pattern of CTLA-4 expression in the cytoplasm of T cells, and little membrane surface labeling.
10. Sperling AI, Bluestone JA. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol Rev. 153:1996;155-182.
11. Herold KC, Vezys V, Koons A, Lenschow D, Thompson C, Bluestone JA. CD28/B7 co-stimulation regulates autoimmune diabetes induced with multiple low doses of Streptozotocin. J Immunol. 158:1997;984-991.
12. Harris N, Peach R, Naemura J, Linsley PS, Le Gros G, Ronchese F. CD80 co-stimulation is essential for the induction of airway eosinophilia. J Exp Med. 185:1997;177-182.
13. Turcovski-Corrales SM, Fenton RG, Peltz G, Taub DD. CD28:B7 interactions promote T cell adhesion. Eur J Immunol. 25:1995;3087-3093.
14. Collins TL, Kassner PD, Bierer BE, Burakoff SJ. Adhesion receptors in lymphocyte activation. Curr Opin Immunol. 6:1994;385-393.
15. Fournier S, Rathwell J, Goodnow C, Allison JP. T cell-mediated elimination of B7.2 transgenic B cells. of special interest Immunity. 6:1997;327-339 This paper describes the T-cell mediated elimination of B cells in mice expressing a B7.2 transgene. These cells are not eliminated in the presence of activated antigen-specific T cells or in the absence of CD28. The authors propose a novel mechanism for maintaining B cell homeostasis by T cells in the absence of an ongoing immune response.
16. Peach RJ, Bajorath J, Brady W, Leytze G, Greene J, Naemura J, Linsley PS. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med. 180:1994;2049-2058.
17. Van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. of special interest J Exp Med. 185:1997;393-404 The binding affinity values of monomeric CTLA-4 and CD28 for B7.1 molecules were determined using surface plasmon resonance and were found to be lower than previously reported. CD28 and CTLA-4 were shown to have binding kinetics which are similar to CD2 - CD58 but faster than TCR - MHC - peptide interactions. The results also demonstrate that CTLA-4 has a dramatically higher avidity than CD28 for B7. See also [18].
18. Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W, Linsley PS. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell co-stimulatory interactions. of special interest J Biol Chem. 271:1996;26762-26771 See annotation [17]. In addition, this study demonstrates the importance of B7 clustering and CTLA-4 homodimerization for the high avidity displayed by CTLA-4 binding to ligand. This has important implications for understanding the balance between CD28 and CTLA-4 ligand binding and resultant signaling.
19. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1:1994;793-801.
20. Morton PA, Fu X-T, Stewart JA, Giacoletto KS, White SL, Leysath CE, Evans RJ, Shieh J-J, Karr RW. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). J Immunol. 156:1996;1047-1054.
21. Linsley PS, Nadler SG, Bajoirath J, Peach R, Leung HT, Rogers J, Bradshaw J, Stebbins M, Leytze G, Brady W, et al. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules. J Biol Chem. 270:1995;15417-15424.
22. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:1994;405-413.
23. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK. Coexpression and functional cooperativity of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med. 176:1992;1595-1604.
24. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. of special interest J Exp Med. 182:1995;459-465 This paper provides the first direct evidence that cross-linking CTLA-4 in vitro provides an inhibitory signal which inhibits proliferation and cytokine production by naive lymph node T cells stimulated with anti-CD3 and anti-CD28 antibodies. See also [41].
25. Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, Lombard DB, Freeman GJ, Nadler LM, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol. 151:1993;3489-3499.
26. Green JM, Noel PJ, Sperling AI, Walnunas TL, Gray GS, Bluestone JA, Thompson CB. Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1:1994;501-508.
27. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, Wang Y, Walunase T, Bluestone J, Listman J. Regulation of CTLA-4 expression during T cell activation. J Immunol. 156:1996;4154-4159.
28. Leung HT, Bradshaw J, Cleaveland JS, Linsley PS. Cytotoxic T lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. of outstanding interest J Biol Chem. 270:1995;1-8 This paper directly demonstrates the distinct protein expression pattern of CTLA-4 and identifies the tyrosine residue in the PI3-K binding motif (YxxM, in single-letter amino acid code; x represents any amino acid) as being essential for the intracellular localization of CTLA-4 in the perinuclear Golgi or post-Golgi compartment.
29. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. of outstanding interest Immunity. 4:1996;535-543 In this paper, the intracellular trafficking of CTLA-4 in activated human T cells is examined. These results demonstrate that CTLA-4 trafficks from the intracellular stores to the surface of the T cells. This expression is vectorial and is directed towards the site of TCR engagement. CTLA-4 is rapidly endocytosed into endosomes, the rate of which is differentially regulated to that of trafficking to the surface.
30. Alegré M-L, Noel PJ, Eisfelder BJ, Chuang E, Clark MR, Reiner SL, Thompson CB. Regulation of surface and intracellular expression of CTLA-4 on mouse T cells. J Immunol. 157:1996;4762-4770.
31. Pawson T. Protein modules and signalling networks. Nature. 373:1995;573-580.
32. Joly M, Kazlauskas A, Fay FS, Corvera S. Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase binding sites. Science. 263:1994;684-687.
33. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW. Differential T cell co-stimulatory requirements in CD28-deficient mice. Science. 261:1993;609-612.
34. Mittrücker H-W, Shahinian A, Bouchard D, Kündig TM, Mak TW. Induction of unresponsiveness and impaired T cell expansion by Stephylococcal enterotoxin B in CD28-deficient mice. J Exp Med. 183:1996;2481-2488.
35. Saha B, Harlan DM, Lee KP, June CH, Abe R. Protection against lethal toxic shock by targeted disruption of the CD28 gene. J Exp Med. 183:1996;2675-2680.
36. Ferguson SE, Han S, Kelsoe G, Thompson CB. CD28 is required for germinal center formation. of special interest J Immunol. 156:1996;4576-4581 This paper demonstrates that germinal centers are not formed in the absence of CD28.
37. Lucas PJ, Negishi I, Nakayama K-I, Fields LE, Loh DY. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol. 154:1995;5757-5768.
38. Kündig T, Shahinian A, Kawai K, Mittrücker H-W, Sebzda E, Bachmann MF, Mak TW, Ohashi PS. Duration of TCR stimulation determines co-stimulatory requirement of T cells. of special interest Immunity. 5:1996;41-52 This paper demonstrates that effective anti-viral responses can be generated in the absence of CD28 if the antigenic peptide is present throughout the duration of the response. This occurs naturally with a virulent virus and can be achieved with repeated peptide injections with a less virulent virus. These results indicate that CD28 is important for sustaining proliferative immune responses.
39. Damle NK, Klussman K, Leytze G, Mydral S, Aruffo A, Ledbetter JA, Linsley PS. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. J Immunol. 152:1994;2686-2697.
40. Walunas TL, Bakker CY, Bluestone JA. CTLA-4-ligation blocks CD28-dependent T cell activation. of outstanding interest J Exp Med. 183:1996;2541-2550 See annotation [41]. In this study CTLA-4 crosslinking inhibited TCR and CD28 stimulation at 72 hours but not at 24 hours after stimulation. It remains to be determined if the differences in the kinetics between these two studies [40,41] is due to the experimental protocols.
41. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. of outstanding interest J Exp Med. 183:1996;2533-2540 This paper confirms and extends the results described in [24]. It demonstrates that CTLA-4-mediated inhibition of anti-CD3/CD28 antibody-induced proliferation of naive lymph node T cells was not due to apoptosis. Rather, CTLA-4 cross-linking blocked entry into the G1 phase of the cell cycle and inhibited the upregulation of CD69 and CD25 as early as 24 hours after stimulation. These results indicate that CTLA-4 may act much earlier than previously proposed [2,52], and suggest that CTLA-4 may regulate the initiation of T cell responses. See also [40].
42. + T cells in vivo is dependent on CD28 co-stimulation and inhibited by CTLA-4. of special interest J Immunol. 155:1995;1032-1036 This is the first demonstration that CTLA-4 blockade can augment antigen-specific T cell responses in vivo. Adoptively transferred TCR transgenic T cells expanded in response to immunization with peptide, and this response was augmented by anti-CTLA-4 antibody treatment. Interestingly, antibody treatment did not alter the kinetics of the downregulation of the response.
43. Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol. 8:1996;519-523.
44. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histological disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol. 73:1996;57-62.
45. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol. 157:1996;1333-1336.
46. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune diseases. J Exp Med. 184:1996;783-788.
47. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. of outstanding interest Science. 271:1996;1734-1736 This report is the first demonstration of the ability of CTLA-4 blocking to enhance T cell mediated responses to tumors in vivo.
48. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shanhinian A, Lee KP, Thompson CB, Griesser H, Mak TW. CTLA-4 deficiency causes lymphoproliferative disorder with early lethality. of outstanding interest Science. 270:1995;985-988 See annotation [49].
49. -/- mice [33,37,indicating that CTLA-4 and CD28 have distinct functions.
50. Chambers CA, Krummel MF, Boitel B, Hurwitz AA, Sullivan TJ, Fournier S, Cassell D, Brunner M, Allison JP. The role of CTLA-4 in the regulation and initiation of T cell responses. Immunol Rev. 153:1996;27-46.
51. Chambers CA, Cado D, Truong T, Allison JP. Thymocyte devlopment is normal in CTLA-4 deficient mice. Proc Natl Acad Sci USA. 1997;. in press.
52. Jenkins MK. The ups and downs of co-stimulation. Immunity. 1:1994;443-446.
53. Su BE, Jacinto M, Hibi T, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal integration during co-stimulation of T lymphocytes. Cell. 77:1994;727-736.
54. Hutchcroft JE, Bierer BE. Signaling through CD28/CTLA-4 family receptors: puzzling participation of phosphatidylinositol-3 kinase. J Immunol. 156:1996;4071-4074.
55. August A, Gibson S, Kawakami Y, Kawakami T, Mills GB, Dupont B. CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. Proc Natl Acad Sci USA. 91:1994;9347-9351.
56. Liao XC, Fournier S, Killeen N, Weiss A, Allison JP, Littman DR. Itk negatively regulates induction of T cell proliferation by CD28 co-stimulation. J Exp Med. 1997;. in press.
57. Marengere LEM, Waterhouse P, Duncan GS, Mittrucker H-W, Feng G-S, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. of special interest Science. 272:1996;1170-1173 This paper demonstrates that a number of molecules known to be involved in TCR signaling are hyperphosphorylated in the T cells from CTLA-4 knockout animals. Furthermore, catalytically active SHP-2 (PTP-1D, SYP) was shown to be bound to cytoplasmic tail of CTLA-4. The authors suggest that this tyrosine phosphatase is essential for the CTLA-4-mediated inhibitory signal by directly dephosphorylating members of the Ras-activating pathway.
58. Law C-L, Craxton A, Otipoby KL, Sidorenko SP, Klaus SJ, Clark EC. Regulation of signalling through B-lymphocyte antigen receptors by cell-cell interaction molecules. Immunol Rev. 153:1996;123-154.
59. Lanier LL. Natural killer cell receptors and MHC class I interactions. of special interest Curr Opin Immunol. 9:1997;126-131 This is a comprehensive review of inhibitory NK receptors, particularly those on human NK cells, including their specificity, function and signal transduction.
60. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA, Cambier JC. Recruitment and activation of PTP-1C in negative regulation of antigen receptor signaling by FcgammaRIIB1. Science. 268:1995;293-297.
61. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet J-P, Long EO. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitory receptor. of special interest Immunity. 4:1996;77-85 This is the first report to provide a molecular mechanism for the KIR- and Ly49-mediated inhibition of cytotoxicity.
62. Chambers CA, Allison JP. The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signaling. Eur J Immunol. 26:1996;3224-3229.
63. Cossette LJ, Hoglinger O, Mou L, Shen SH. Localization and down-regulating role of the protein tyrosine phosphatase PTP2C in membrane ruffles of PDGF-stimulated cells. Exp Cell Res. 223:1996;459-466.
64. Li W, Nishimura R, Kashishian A, Batzer AG, Kim WJ, Cooper JA, Schlessinger J. A new function for a phosphotyrosine phosphatase: linking Grb2-Sos to a receptor tyrosine kinase. Mol Cell Biol. 14:1994;509-517.
65. Vieira AV, Lamaze C, Schmid SL. Control of EGF receptor signaling by clathrin-mediated endocytosis. of special interest Science. 274:1996;2086-2089 This study demonstrates that the endocytosis rates and intracellular trafficking of a receptor tyrosine kinase, namely, EGFR, can influence the signaling pathways utilized. Normal intracellular trafficking is essential for tyrosine phosphorylation and for attenuating EGFR signaling. Most interestingly, the results suggest that intracellular compartmentalization can regulate the engagement of distinct signaling pathways.
66. + T cells responding to a bacterial superantigen. J Immunol. 154:1995;4302-4308.
67. Van Parijs L, Ibraghimov A, Abbas AK. The roles of co-stimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity. 4:1996;321-328.
68. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature. 377:1995;348-351.
69. Lin R-H, Hwang Y-W, Yang B-C, Lin C-S. TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 co-stimulation. J Immunol. 158:1997;598-603.
70. Tivol EA, Schweitzer AN, Sharpe AH. Costimulation and autoimmunity. Curr Opin Immunol. 8:1996;822-830.
71. Allison JP, Hurwitz AA, Leach DR. Manipulation of co-stimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 7:1995;682-686.
72. Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellstrsm I, Hellstrsm KE, Marquardt H, Chen L. B7-CD28 co-stimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med. 183:1996;791-800.
73. + T cells. J Immunol. 158:1997;637-642.
74. Huang AY, Golumbek P, Ahmadzdeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965.
75. -T lymphocytes by 4-1BB ligand. J Immunol. 158:1997;551-559.
76. Reinhold MI, Lindberg FP, Kersh GJ, Allen PM, Brown EJ. Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion- dependent CD28-independent signaling pathway. J Exp Med. 185:1997;1-11.
77. Raulet DH, Held W, Correa I, Dorfman JR, Wu M-F, Corral L. Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunol Rev. 155:1997;41-52.
78. Olcese L, Lang P, Vely F, Cambiaggi A, Marguet D, Blery M, Hippen KL, Biassoni R, Moretta A, Morstta L, et al. Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J Immunol. 156:1996;4531-4534.
79. Phillips JH, Gumperz JE, Parham P, Lanier LL. Superantigen-dependent, cell-mediated cytotoxicity inhibited by MHC class I receptors on T lymphocytes. of special interest Science. 268:1995;403-405 Demonstration that KIRs expressed on activated T cells can inhibit proliferative and cytokine responses to superantigens in the presence of the appropriate HLA molecules. The importance of these inhibitory receptors for regulating T cell responses in vivo is unknown.
80. + T cells. Curr Opin Immunol. 7:1995;367-374.
81. Mason LH, Anderson SK, Yokoyama WM, Smith HRC, Winkler-Pickett R, Ortaldo JR. The Ly-49D receptor activates murine natural killer cells. J Exp Med. 184:1996;2119-2128.
82. Mandelboim O, Davis DM, Reyburn HT, Valés-Gómez M, Sheu EG, Pazmany L, Strominger JL. Enhancement of class II-restricted T cell responses by co-stimulatory NK receptors for class I MHC proteins. Science. 274:1996;2097-2100.
83. Sprent J, Tough DF. Lymphocyte life-span and memory. Science. 265:1994;1395-1400.